Condition: Type2diabetes · PreDiabetes · Renal Failure · Sponsor: University Hospital Tuebingen
More than 50% of patients with type 2 diabetes develop micro- and/or macrovascular complications during the course of the disease. Additionally, many patients at risk for diabetes develop metabolically driven complications including kidney and heart disease. Thus, it is of utmost importance to improve prevention of T2D and with this complications. Remission of prediabetes, i.e. normalization of hyperglycemia by means of lifestyle intervention is one of the most effective ways to prevent the development of T2D and complications. Novel sub-phenotyping analysis identified clusters of risk for diabetes associated with different complications, opening opportunities to new therapeutic approaches, despite and in addition to lifestyle changes. So far, pharmacological therapy is not indicated for patients with prediabetes. Remission of hyperglycemia associated with prediabetes during lifestyle interventions not only prevents T2D but is also linked with reduced albuminuria and lower microvascular and kidney complications. Thus, reaching normoglycemia (i.e. prediabetes remission) is important for reducing the risk of (pre-)diabetes-associated complications including micro- and even macrovascular disease. In patients with T2D, recent data show that dapagliflozin can improve diabetes remission, and thus, likely complications. However, to date no data have assessed whether or not this is also true in patients with hyperglycemia related to prediabetes which, as outlined above, already cause…
This description comes directly from the study's public registry record.
Andreas Birkenfeld, Prof. Dr. · 0049707129 · andreas.birkenfeld@med.uni-tuebingen.de
Andreas Fritsche, Prof. Dr. · 0049707129 · andreas.fritsche@med.uni-tuebingen.de
Always discuss trial participation with your own doctor first.
| Charité Universitätsmedizin Berlin, Klinik für Endokrinologie und Stoffwechselmedizin | Berlin, Germany | Recruiting |
| Universitätsstudienzentrum für Stoffwechselerkrankungen , Medizinische Klinik und Poliklinik III | Dresden, Germany | Recruiting |
| German Diabetes Center, Leibniz-Center for Diabetes Research at the Heinrich-Heine-University Duesseldorf | Düsseldorf, Germany | Recruiting |
| Heidelberg University Hospital - Department of Endocrinology and Metabolism | Heidelberg, Germany | Recruiting |
| Medizinische Klinik und Poliklinik III - Bereich Endokrinologie | Leipzig, Germany | Recruiting |
| Medizinische Klinik I, UKSH Campus LübeckAG Meyhöfer - Endocrinology, Diabetes & Metabolism | Lübeck, Germany | Not Yet Recruiting |
| Diabetes Center Med. Klinik und Poliklinik IV, Klinikum der Universität München, LMU | München, Germany | Recruiting |
| Institut für Ernährungsmedizin, Technische Universität München | München, Germany | Not Yet Recruiting |
| University Hospital Tuebingen, Otfried-Mueller Str. 10 | Tübingen, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06054035